Importantly, PSMA-DMAb retained the ability to recognize PSMA on the surface of implanted tumor cells and to mediate a potent anti-tumor response in vivo, due at least in part through interacting with NK cells to mediate ADCC/ADCP of tumor cells. This evidence concerns the gene FOLH1 and neoplasm.